Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase NA 1Phase 1/2 1Phase 1 1

Status

Terminated 3Completed 2Unknown 1

Sponsor Class

OTHER 4INDUSTRY 2

Study Type

Interventional 6

Sponsor

Cancer Type

Thoracic 4

Conditions

Carcinoma, Non-Small-Cell Lung 307Lung Neoplasms 111Pancreatic Neoplasms 70Neoplasms 56Neoplasm Metastasis 32Brain Neoplasms 31Head and Neck Neoplasms 26Squamous Cell Carcinoma of Head and Neck 25Breast Neoplasms 25Glioblastoma 24Adenocarcinoma of Lung 23Gliosarcoma 22Non-Squamous Non-Small Cell Lung Cancer 21Colorectal Neoplasms 18Carcinoma, Hepatocellular 17Adenocarcinoma, Bronchiolo-Alveolar 16Rectal Neoplasms 13Colonic Neoplasms 13Carcinoma, Renal Cell 13Glioma 12Esophageal Neoplasms 11Astrocytoma 11Central Nervous System Neoplasms 9Carcinoma, Squamous Cell 9Salivary Gland Neoplasms 8Prostatic Neoplasms 8Oligodendroglioma 8Gallbladder Neoplasms 8Adenocarcinoma 8Ovarian Neoplasms 7

Interventions

Cyclophosphamide 155Dexamethasone 141Rituximab 85fludarabine 80Lenalidomide 72Cytarabine 70Bortezomib 65fludarabine phosphate 63Gemcitabine 62venetoclax 55pomalidomide 53Etoposide 53pembrolizumab 52Paclitaxel 48Cisplatin 48Carboplatin 48Peripheral Blood Stem Cell Transplantation 47Filgrastim 40Radiotherapy 39Busulfan 37Calcium Dobesilate 36Methotrexate 34Melphalan 34Bevacizumab 33carfilzomib 32Cyclosporine 32Azacitidine 32Mycophenolic Acid 30Vincristine 29Bendamustine Hydrochloride 29

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Recurrence × Erlotinib Hydrochloride × Clear all
NCT01032070 2024-12-12

PETEY

Astellas Pharma Inc

Phase 2 Terminated
25 enrolled 23 charts

Familial ependymoma, Ependymoma, Recurrence

NCT01233687 2017-06-22

AMG 102 and Erlotinib for Advanced Non-Small Cell Lung Cancer

University of Pittsburgh

Phase 1/2 Completed
49 enrolled 8 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Recurrence

NCT02015728 2016-12-15

SEED

Seattle Children's Hospital

Phase NA Unknown
20 enrolled

Neoplasms, Recurrence

NCT01515969 2016-07-12

Phase 1 Erlotinib and Dovitinib (TKI258) in Advanced Non-small Cell Lung Cancer (NSCLC)

Stanford University

Phase 1 Terminated
9 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Recurrence

NCT01189435 2015-11-18

Erlotinib Re-Challenge for Recurrent EGFR-mutant Lung Cancer in Patients Who Previously Received Adjuvant Erlotinib or Gefitinib

Memorial Sloan Kettering Cancer Center

Phase 2 Terminated
2 enrolled 3 charts
Thoracic

Lung Neoplasms, Recurrence

NCT00095225 2008-01-29

A Study to Evaluate Bevacizumab and Chemotherapy or Tarceva in Treating Recurrent or Refractory NSCLC (Non-Small Cell Lung Cancer)

Genentech, Inc.

Phase 2 Completed
122 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Recurrence, Local, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡